BioLargo (NASDAQ:BLGO – Get Free Report) is one of 34 publicly-traded companies in the “Chemicals & allied products” industry, but how does it contrast to its competitors? We will compare BioLargo to related businesses based on the strength of its profitability, analyst recommendations, earnings, risk, dividends, institutional ownership and valuation.
Analyst Recommendations
This is a summary of recent recommendations for BioLargo and its competitors, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
BioLargo | 0 | 0 | 0 | 0 | N/A |
BioLargo Competitors | 139 | 1274 | 1593 | 46 | 2.51 |
As a group, “Chemicals & allied products” companies have a potential upside of 9.03%. Given BioLargo’s competitors higher probable upside, analysts clearly believe BioLargo has less favorable growth aspects than its competitors.
Valuation & Earnings
Gross Revenue | Net Income | Price/Earnings Ratio | |
BioLargo | $12.23 million | -$3.50 million | -8.19 |
BioLargo Competitors | $6.64 billion | $206.77 million | 66.19 |
BioLargo’s competitors have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
BioLargo has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s competitors have a beta of 1.78, suggesting that their average share price is 78% more volatile than the S&P 500.
Insider and Institutional Ownership
0.0% of BioLargo shares are owned by institutional investors. Comparatively, 68.4% of shares of all “Chemicals & allied products” companies are owned by institutional investors. 20.3% of BioLargo shares are owned by insiders. Comparatively, 10.1% of shares of all “Chemicals & allied products” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares BioLargo and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
BioLargo | -16.53% | -58.35% | -32.12% |
BioLargo Competitors | -568.74% | 5.73% | -0.15% |
Summary
BioLargo competitors beat BioLargo on 8 of the 10 factors compared.
BioLargo Company Profile
BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.